On this page
Back to topAlamar Biosciences ALMR
Alamar Biosciences listed on Nasdaq on 17 Apr 2026 and is not in the S&P 500. It is worth $2.0 billion. Its price history starts on 17 Apr 2026. 7 directors have filed with the SEC in the last 12 months (who counts), 2 of them executives. 3 other officers are on file. At 30 Jun 2026, Sands Capital Alternatives was its largest institutional holder, with 6.1% of the company.
- CEO
- Yuling Luo
- Listed
- 17 Apr 2026 on Nasdaq, IPO filings and terms
- Headquarters
- Fremont, CA
- Market cap
- $2.0B
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Financial history
Twelve months to 30 Sep 2026, from Alamar Biosciences's quarterly filings.
Quarters since Mar 2025
- P/E
- -
- No profit over the last four quarters
Quarterly results
Each quarter's revenue, net income and free cash flow.
Mar 2025 to Sep 2026
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2026 | $34M | $-13M |
| Jun 2026 | $29M | $-13M |
| Mar 2026 | $26M | $-21M |
| Sep 2025 | $20M | $-8M |
| Jun 2025 | $16M | $-7M |
| Mar 2025 | $13M | $-8M |
Revenue breakdown
Alamar Biosciences's $34M of revenue, as its quarterly report splits it. Parts that are not a business, such as sales between segments, can be negative.
Quarter to Sep 2026
| Split by | Part | Revenue |
|---|---|---|
| Product | Consumables | $18M |
| Product | Instruments | $8M |
| Product | Service | $7M |
| Region | US | $23M |
| Region | EMEA | $7M |
| Region | Asia Pacific | $3M |
| Region | Americas | $953,000 |
Alamar Biosciences's market cap since April 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $2.1B |
Download Alamar Biosciences's data as JSON, with the weekly market caps in billions of dollars from 17 Apr 2026.
Board and leadership
Board and officers
1 person here also holds roles at other S&P 500 companies.
Roles filed up to 30 Sep 2026
| Name | Title |
|---|---|
| Directors (7) | |
| Yuling LuoChief Executive Officer | |
| Rebecca ChambersDirector | |
| Shiping ChenChief Operating Officer | |
| Nicholas NaclerioDirector | |
| Robert P. RagusaDirector | |
| Ian W. RatcliffeDirector | |
| Frank WitneyDirectorAlso at Revvity | |
| Officers (3) | |
| Justin J. McAnearChief Financial OfficerLast filed 20 Apr 2026 | |
| John L. BrottemGeneral CounselLast filed 16 Sep 2026 | |
| Timothy Ogden WhitePresidentLast filed 20 Apr 2026 | |
Owners and trading
Largest institutional holders
Each fund group's share of Alamar Biosciences. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers made no open-market sales and bought $4.0 million in 1 purchase in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 20 Apr 2026Buy | Nicholas NaclerioDirector | $4.0M |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
1 departure and 1 appointment of directors and officers in the last two years.
Events, newest first
- 30 Oct 2026 Timothy "Tod" White retiredPresident, effective 31 Dec 2026
- 28 Aug 2026 Robert Ragusa appointedDirector, effective 1 Sep 2026
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.